Clinical Trial: Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization

Brief Summary: Purpose: To determine the efficacy and safety of one commonly used VEGF inhibitor, bevacizumab (Avastin, Genentech), as a topical agent for the treatment of corneal neovascularization.

Detailed Summary:
Sponsor: Walter Reed Army Medical Center

Current Primary Outcome: Adverse Events (Ocular and Systemic) [ Time Frame: 24 weeks ]

Original Primary Outcome:

Current Secondary Outcome: Size and Extent of Corneal Neovascularization [ Time Frame: 24 weeks ]

computerized image analysis of the corneal photographs were used to measure the change in size and extent of corneal neovascularization from baseline.


Original Secondary Outcome:

Information By: Walter Reed Army Medical Center

Dates:
Date Received: August 6, 2007
Date Started: August 2007
Date Completion:
Last Updated: July 3, 2013
Last Verified: July 2013